Pergoveris 150/75 IU Vial is a prescription fertility medicine containing two recombinant gonadotropins: follitropin alfa and lutropin alfa. Each powder vial provides 150 IU of recombinant follicle-stimulating hormone and 75 IU of recombinant luteinising hormone. It is indicated for follicular development in adult women with severe deficiencies of both hormones, under specialist supervision.
Administration must follow an individual plan established by a fertility specialist. The medicine is given by subcutaneous injection after reconstitution with the supplied solvent. A healthcare professional should demonstrate preparation, injection technique and safe disposal before any self-administration. The prescribed dose and monitoring schedule depend on ovarian response. Do not change the dose independently. The prepared solution is intended for immediate, single use and must not be stored for later injection. Do not administer a solution containing visible particles. This medicine requires ultrasound and, where appropriate, hormonal monitoring throughout the prescribed course.
Follitropin alfa acts through follicle-stimulating hormone receptors to support the development of ovarian follicles. Lutropin alfa provides luteinising hormone activity, contributing to the hormonal processes involved in follicular growth and maturation. Their combined action supplies the two gonadotropin activities required in patients with severe FSH and LH deficiency. Pergoveris 150/75 IU Vial is administered within a specialist-directed fertility protocol, with subsequent steps determined by clinical monitoring and individual ovarian response.
The powder contains sucrose, disodium phosphate dihydrate, sodium dihydrogen phosphate monohydrate, methionine and polysorbate 20. Sodium hydroxide and concentrated phosphoric acid are used for pH adjustment. The accompanying solvent contains water for injections. The active substances are manufactured using recombinant DNA technology.
This prescription formulation provides both recombinant FSH and LH activity in one reconstituted injection for an established specialist indication. Its combined composition supports individually monitored fertility care.
The 150/75 IU powder-and-solvent presentation is registered with Merck Serono S.A. in Switzerland as manufacturer in Singapore's medicines register. Manufacturing details can vary by market presentation. Store below 25°C in the original packaging to protect from light. It is available at Pharmacy Plus Kuwait.
KWD
